Clinical Trial Update: Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Patients With Bipolar Depression [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating quetiapine fumarate (SEROQUEL) for bipolar depression has completed, with reported safety and efficacy outcomes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Depression
• Bipolar Disorder

Drugs mentioned

• SEROQUEL (QUETIAPINE)

Snippet

Sponsor: AstraZeneca | Conditions: Bipolar Disorder, Depression, Bipolar | Phase 3 | Status: COMPLETED